Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business
- Start of clinical trial and first safety data with HDP-101 in multiple myeloma
- Conclusion and implementation of a strategic partnership with Huadong Medicine
- Successful financing activities
- Financials in line with adjusted guidance
- Conference call to be held on 27 March 2023 at 03:00 pm CEST
Heidelberg Pharma AG today published its financial results and Annual Report for fiscal year 2022 (1 December 2021 – 30 November 2022) and its outlook for 2023.